Medical technology company Medtronic PLC (NYSE: MDT) has announced the results of the Enable Hernia Repair clinical study for the Hugo robotic-assisted surgery (RAS) system used in inguinal and ventral hernia repair procedures. The study, which involved 193 patients, showed that the surgical success rate with the Medtronic Hugo RAS system was 100%. This prospective, multi-center, single-arm pivotal study is the first Investigational Device Exemption (IDE) clinical trial completed in the U.S. for robotic-assisted hernia surgery. Medtronic stock saw an increase following this news. For more detailed information, visit Benzinga.com.